Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
Compared to individuals with obesity of other etiologies matched for BMI (body mass index), they have lower levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides
Nkeck JR, Ida CM, Koe VN, Ndam AWN, Ync J, Eo M, et al
It is unopened, unused and in its original saleable condition The product is not one on which a change of mind return is not available ( If these requirements are not satisfied Pharmacy Junction reserves the right not to offer an exchange or refund for change of mind returns
Trial averages are population-level statistics, not guarantees
Novo and Eli Lilly have already faced stiff competition from smaller compounders of weight-loss drugs
